Oliver Rausch is Chief Scientific Officer at Storm Therapeutics Ltd. Storm is a spin-out from Cambridge University targeting RNA modification pathways for the development of new first-in-class cancer treatments. As CSO, Oliver has overall responsibility for developing Storm’s RNA modification analysis platform, and for delivering small molecule drugs from its drug discovery pipeline. Prior to Storm, Oliver was Programme Director at the National Institute for Health Research (NIHR) where he led the Translational Research Partnerships (TRPs) and other industry-focussed collaboration programmes in experimental medicine and early drug development. Oliver has over twenty years’ of drug discovery experience in Inflammation, Neurology and Oncology from organisations such as GlaxoSmithKline, UCB Celltech and Cellzome. He holds a degree in Biochemistry from the Free University in Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.